Ambeed.cn

首页 / / / / psoralidin/补骨脂定

psoralidin/补骨脂定 {[allProObj[0].p_purity_real_show]}

货号:A643159

psoralidin是一种从补骨脂(Psoralea corylifolia L.)中分离出的天然呋喃香豆素,具有抗癌和化学预防特性,能够抑制Akt磷酸化和磷脂酰肌醇3-激酶的激活。

psoralidin/补骨脂定 化学结构 CAS号:18642-23-4
psoralidin/补骨脂定 化学结构
CAS号:18642-23-4
psoralidin/补骨脂定 3D分子结构
CAS号:18642-23-4
psoralidin/补骨脂定 化学结构 CAS号:18642-23-4
psoralidin/补骨脂定 3D分子结构 CAS号:18642-23-4
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

psoralidin/补骨脂定 纯度/质量文件 产品仅供科研

货号:A643159 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
Cell, 2025. Ambeed. [ A122167 ]
Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >
产品名称 Akt Akt1 Akt2 Akt3 其他靶点 纯度
Honokiol MEK 98%
PF-04691502 ++++

P-Akt (S473), IC50: 3.8 nM

P-Akt (T308), IC50: 7.5 nM

98+%
PHT-427 +

Akt, Ki: 2.7 μM

99%+
Deguelin PI3K 99%+
TIC10 isomer ERK 98+%
Perifosine +

Akt, IC50: 4.7 μM

98%
Miltefosine PKC,PI3K 98%
Triciribine +

Akt, IC50: 130 nM

99%+
Uprosertib +

Akt1, IC50: 180 nM

+

Akt2, IC50: 328 nM

++

Akt3, IC50: 38 nM

99%+
Afuresertib ++++

Akt1, Ki: 0.08 nM

++++

Akt2, Ki: 2 nM

++++

Akt3, Ki: 2.6 nM

99%+
Miransertib ++++

Akt1, IC50: 5 nM

++++

Akt2, IC50: 4.5 nM

++

Akt3, IC50: 16 nM

98+%
GSK-690693 ++++

Akt1, IC50: 2 nM

+++

Akt2, IC50: 13 nM

+++

Akt3, IC50: 9 nM

99%+
AT7867 ++

Akt1, IC50: 32 nM

++

Akt2, IC50: 17 nM

++

Akt3, IC50: 47 nM

PKA 99%+
AKT inhibitor VIII ++

Akt1, IC50: 58 nM

+

Akt2, IC50: 210 nM

+

Akt3, IC50: 2119 nM

97%
MK-2206 2HCl +++

Akt1, IC50: 8 nM

+++

Akt2, IC50: 12 nM

+

Akt3, IC50: 65 nM

99%+
Ipatasertib ++++

Akt1, IC50: 5 nM

++

Akt2, IC50: 18 nM

+++

Akt3, IC50: 8 nM

99%+
AT13148 ++

Akt1, IC50: 38 nM

+

Akt2, IC50: 402 nM

++

Akt3, IC50: 50 nM

PKA 95%
Capivasertib ++++

Akt1, IC50: 3 nM

+++

Akt2, IC50: 8 nM

+++

Akt3, IC50: 8 nM

99%+
A-674563 HCl +++

Akt1, Ki: 11 nM

PKA 99%
CCT128930 +++

Akt2, IC50: 6 nM

PKA 95%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

psoralidin/补骨脂定 生物活性

描述 Psoralidin is a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation, with anti-cancer, anti-bacterial, and anti-inflammatory properties[3]. Three breast cancer cell populations (ALDH- cells, ALDH+ cells, and commercial BSCSs) are sensitive to Psoralidin treatment (10, 15, 20, and 25 μM; 24 hours) with IC50s ranging from 18 to 21 μM; however, the MCF-12A cells were resistant to Psoralidin. Psoralidin (30 μM; 24 hours) results in a significant induction of apoptosis for ALDH- cells, ALDH+ cells, and commercial BCSCs[4]. Psoralidin decreased the viability of the liver cancer HepG2 cells and exhibited an IC50 of 9 µM. Also, Psoralidin exerted very low toxic effects on the normal AML12 hepatocytes exhibiting an IC50 of 100 µM[5]. Psoralidin treatment could reverse the caffeine-induced dysfunctions and aberrant differentiation of BMSCs (bone marrow mesenchymal stem cells) via the ER pathway[6].

psoralidin/补骨脂定 细胞实验

Cell Line
Concentration Treated Time Description References
PC-3 cells 60 µM 24 hours Psoralidin inhibited viability and induced apoptosis in PC-3 cells Apoptosis. 2010 Feb;15(2):153-61
HL-1 cardiomyocytes 10, 20, 50, 100 µM 24 hours Evaluate the toxic effects of psoralidin on HL-1 cardiomyocytes, showing no significant toxicity at concentrations ≤50 μM. J Adv Res. 2022 Sep;40:249-261
Commercial breast cancer stem cells (BCSCs) 10, 15, 20, 25 µM 24 hours To evaluate the effect of psoralidin on cell viability, results showed that psoralidin significantly inhibited the growth of BCSCs with IC50 values ranging from 18-21 μM Br J Cancer. 2013 Nov 12;109(10):2587-96
MDA-MB-231 cells (ALDH+) 10, 15, 20, 25 µM 24 hours To evaluate the effect of psoralidin on cell viability, results showed that psoralidin significantly inhibited the growth of ALDH+ cells with IC50 values ranging from 18-21 μM Br J Cancer. 2013 Nov 12;109(10):2587-96
MDA-MB-231 cells (ALDH-/C0) 10, 15, 20, 25 µM 24 hours To evaluate the effect of psoralidin on cell viability, results showed that psoralidin significantly inhibited the growth of ALDH-/C0 cells with IC50 values ranging from 18-21 μM Br J Cancer. 2013 Nov 12;109(10):2587-96
DU-145 cells 45 µM 24 hours Psoralidin inhibited viability and induced apoptosis in DU-145 cells Apoptosis. 2010 Feb;15(2):153-61
MG63 cells 0–50 µM 24 or 48 hours PSO inhibited OS cell proliferation in a dose-dependent and time-dependent manner. Chin Med. 2023 Mar 31;18(1):34
143B cells 0–50 µM 24 or 48 hours PSO inhibited OS cell proliferation in a dose-dependent and time-dependent manner. Chin Med. 2023 Mar 31;18(1):34
HL-1 cardiomyocytes 20 µM 3 hours Psoralidin pretreatment significantly increased cell viability, reduced apoptosis rate, intracellular ROS generation, and LDH release. J Adv Res. 2022 Sep;40:249-261
DU-145 cells 45 µM 30 and 60 minutes Psoralidin inhibited both constitutive and epidermal growth factor (EGF)-induced EGFR activation and simultaneously triggered SAPK signaling, resulting in the induction of apoptosis in AIPC cells. Mol Cancer Ther. 2010 Sep;9(9):2488-96
PC-3 cells 60 µM 30 and 60 minutes Psoralidin inhibited both constitutive and epidermal growth factor (EGF)-induced EGFR activation and simultaneously triggered SAPK signaling, resulting in the induction of apoptosis in AIPC cells. Mol Cancer Ther. 2010 Sep;9(9):2488-96
Ichthyophthirius multifiliis theronts 0.8 mg/L or higher 4 hours Evaluate the killing effect of psoralidin on I. multifiliis theronts, results showed that at 0.8 mg/L or higher concentrations, all theronts were killed within 4 hours Int J Parasitol Drugs Drug Resist. 2015 Apr 21;5(2):58-64
Human lung adenocarcinoma cell lines (A549) 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100, 300 µg/mL 48 hours To evaluate the cytotoxicity of psoralidin and its nanoformulation on A549 cells. Results showed that Ps-CS/BLs had an IC50 value of 3.56 ± 0.36 µg/mL, significantly lower than free psoralidin (48.94 ± 1.3 µg/mL). Polymers (Basel). 2023 Mar 15;15(6):1464
Human breast cancer cell lines (MCF-7) 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100, 300 µg/mL 48 hours To evaluate the cytotoxicity of psoralidin and its nanoformulation on MCF-7 cells. Results showed that Ps-CS/BLs had an IC50 value of 1.19 ± 0.24 µg/mL, significantly lower than free psoralidin (39.85 ± 1.1 µg/mL). Polymers (Basel). 2023 Mar 15;15(6):1464
HeLa cells 20-50 µM 48 hours To evaluate the cytotoxic and apoptotic activities of psoralidin in HeLa cells. Results showed that psoralidin induced apoptosis in a concentration-dependent manner, with 13.5 ± 1.2% apoptosis at 50 μM. Molecules. 2012 May 29;17(6):6449-64

psoralidin/补骨脂定 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice ADR-induced cardiotoxicity model Intraperitoneal injection 12.5, 25, 50 mg/kg Every two days, three times in total Psoralidin significantly increased the survival rate of ADR-injured mice, improved cardiac function indicators, and reduced myocardial fibrosis, oxidative stress, and apoptosis. J Adv Res. 2022 Sep;40:249-261
Goldfish (Carassius auratus) I. multifiliis infection model Water bath administration 2.5 mg/L 5 hours Evaluate the in vivo therapeutic effect of psoralidin on I. multi?liis infected gold?sh, results showed that 2.5 mg/L concentration for 5 hours significantly reduced the number of theronts released Int J Parasitol Drugs Drug Resist. 2015 Apr 21;5(2):58-64
Balb/c nude mice CTPE xenograft model Oral 20 mg/kg 5 days per week for 4-5 weeks Oral administration of Psoralidin significantly suppressed CTPE xenograft growth without observable toxicity. Tumours from Pso-treated animals showed decreased autophagic morphology, mesenchymal markers expression, and increased epithelial protein expression. Br J Cancer. 2017 Jun 27;117(1):56-64
Balb/c athymic nude mice ALDH+, CD44+/CD22− and ALDH− xenograft models Oral 25 mg/kg 5 days a week for 4 weeks Psoralidin significantly inhibited the growth of ALDH+, CD44+/CD22? and ALDH? tumors and inhibited Notch-1 mediated EMT activation. Mol Carcinog. 2017 Mar;56(3):1127-1136
BALB/c nude mice Orthotopic osteosarcoma mouse model Oral gavage 5, 10, or 20 mg/kg Every two days for three weeks PSO significantly inhibited osteosarcoma growth and metastasis. Chin Med. 2023 Mar 31;18(1):34
Mice PC-3 xenograft model Oral 50 mg/kg Not specified Psoralidin inhibited tumor growth and induced apoptosis Apoptosis. 2010 Feb;15(2):153-61
Nude mice PC-3 xenograft model Oral 50 mg/kg Five days a week for four weeks Psoralidin effectively suppressed PC-3 xenograft tumors by inhibiting EGFR-mediated survival signaling with a simultaneous induction of SAPK-mediated apoptotic events. Mol Cancer Ther. 2010 Sep;9(9):2488-96

psoralidin/补骨脂定 参考文献

[1]Sun H, Ma Z, et al. Regio- and isoform-specific glucuronidation of psoralidin: evaluation of 3-o-glucuronidation as a functional marker for UGT1A9. J Pharm Sci. 2015 Jul;104(7):2369-77.

[2]Liu X, Nam JW, et al. Psoralidin, a coumestan analogue, as a novel potent estrogen receptor signaling molecule isolated from Psoralea corylifolia. Bioorg Med Chem Lett. 2014 Mar 1;24(5):1403-6.

[3]Yang HJ, Youn H, Seong KM, Yun YJ, Kim W, Kim YH, Lee JY, Kim CS, Jin YW, Youn B. Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation. Biochem Pharmacol. 2011 Sep 1;82(5):524-34

[4]Suman S, Das TP, Damodaran C. Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells. Br J Cancer. 2013 Nov 12;109(10):2587-96

[5]Li J, Fu Y, Hu X, Xiong Y. Psoralidin inhibits the proliferation of human liver cancer cells by triggering cell cycle arrest, apoptosis and autophagy and inhibits tumor growth in vivo. J BUON. 2019 Sep-Oct;24(5):1950-1955

[6]Hua R, Zou J, Ma Y, Wang X, Chen Y, Li Y, Du J. Psoralidin prevents caffeine-induced damage and abnormal differentiation of bone marrow mesenchymal stem cells via the classical estrogen receptor pathway. Ann Transl Med. 2021 Aug;9(15):1245

psoralidin/补骨脂定 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.97mL

0.59mL

0.30mL

14.87mL

2.97mL

1.49mL

29.73mL

5.95mL

2.97mL

psoralidin/补骨脂定 技术信息

CAS号18642-23-4
分子式C20H16O5
分子量 336.34
SMILES Code O=C1C2=C(OC3=CC(O)=CC=C32)C4=C(O1)C=C(O)C(CC=C(C)C)=C4
MDL No. MFCD10566617
别名
运输蓝冰
InChI Key YABIJLLNNFURIJ-UHFFFAOYSA-N
Pubchem ID 5281806
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C

溶解方案

DMSO: 50 mg/mL(148.66 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案 一
方案 二
AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。